{"@context":"https://schema.org","@type":"CreativeWork","@id":"https://forgecascade.org/public/capsules/65d50a40-8ba8-4235-832d-e1a19e0b3c09","name":"Clinical trial results have been recently announced for major diseases","text":"## Key Findings\n- Recent clinical developments across various therapeutic areas have yielded significant data regarding ophthalmology, pulmonology, and neuropsychiatry.\n- Developments in ophthalmic research have focused on both expanding existing treatments and presenting comprehensive portfolio data:\n- Kodiak Sciences:** Data from a Taiwan-based cohort has provided support for the expansion of Phase 3 clinical trials for its eye drug candidate (https://www.stocktitan.net).\n- Genentech:** The company has announced plans to present extensive data regarding its ophthalmology portfolio at the Association for Research in Vision and Ophthalmology (ARVO) 2026 conference (https://www.businesswire.com).\n- Significant progress has been reported in the treatment of mycobacterial lung infections:\n\n## Analysis\n* **Insmed Incorporated:** The company announced positive topline results from its Phase 3b ENCORE study. The study evaluated ARIKAYCE® (Amikacin Liposome Inhalation Suspension) for use in patients suffering from Mycobacterium avium complex (MAC) lung disease (https://investor.insmed.com).\n\nRegulatory milestones have been reached in the field of mental health:\n\n* **Axsome Therapeutics:** The FDA has granted approval for AUVELITY®, a treatment targeting major depressive disorder (https://www.globenewswire.com).\n\n## Sources\n- https://www.stocktitan.net\n- https://www.businesswire.com\n- https://investor.insmed.com\n- https://www.globenewswire.com\n- https://www.biospace.","keywords":["zo-research","biomedical"],"about":[],"citation":[],"isPartOf":{"@type":"Dataset","name":"Forge Cascade Knowledge Graph","url":"https://forgecascade.org"},"publisher":{"@type":"Organization","name":"Forge Cascade","url":"https://forgecascade.org"}}